Accumulating preclinical data suggest that compounds that block the excitatory effect of glutamate on the kainate subtype of glutamate receptors may have utility for the treatment of pain, migraine, and epilepsy. In the present study, the in vitro pharmacological properties of the novel glutamate antagonist 5-carboxyl-2,4-di-benzamido-benzoic acid (NS3763) are described. In functional assays in human embryonic kidney (HEK)293 cells expressing homomeric GLU K5 or GLU K6 receptors, NS3763 is shown to display selectivity for inhibition of domoate-induced increase in intracellular calcium mediated through the GLU K5 subtype (IC 50 ϭ 1.6 M) of kainate receptors compared with the GLU K6 subtype (IC 50 Ͼ 30 M). NS3763 inhibits the GLU K5 -mediated response in a noncompetitive manner and does not inhibit [
tors compared with the GLU K6 subtype (IC 50 Ͼ 30 M). NS3763 inhibits the GLU K5 -mediated response in a noncompetitive manner and does not inhibit [ 3 H]␣-amino-3-hydroxy-5-tertbutylisoxazole-4-propionic acid binding to GLU K5 receptors. Furthermore, NS3763 selectively inhibits L-glutamate-and domoate-evoked currents through GLU K5 receptors in HEK293 cells and does not significantly inhibit ␣-amino-3-hydroxy-5-methylisoxazole-4-propionic acid-or N-methyl-D-aspartate-induced currents in cultured mouse cortical neurons at 30 M. This is the first report on a selective and noncompetitive GLU K5 antagonist.
Glutamate is the major excitatory neurotransmitter in the central nervous system and is involved in both physiological and pathological events in the brain through activation of G protein-coupled metabotropic receptors as well as a trio of ionotropic receptor families consisting of N-methyl-D-aspartate (NMDA) receptors, ␣-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, and kainate receptors (Collingridge and Lester, 1989; Schoepp et al., 1999) . The pharmacology of NMDA and AMPA/kainate receptors has been studied thoroughly. Selective competitive NMDA antagonists such as D-2-amino-5-phosphovaleric acid (APV; Davies et al., 1981) , noncompetitive antagonists such as (Ϫ)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate (Wong et al., 1986) , and the competitive AMPA/kainate receptor antagonists 6-cyano-2,3-dihydroxy-7-nitroquinoxaline and NBQX Sheardown et al., 1990) have aided in the understanding of the physiological role of these two groups of receptors. The pharmacological isolation of kainate receptors has been very difficult because AMPA receptor activation masks the existence of kainate receptors in essentially every central neuron, and the competitive AMPA/kainate receptor antagonists 6-cyano-2,3-dihydroxy-7-nitroquinoxaline and NBQX have provided limited information because they display very poor selectivity at AMPA versus kainate receptors Lodge et al., 1991) . However, low concentrations of NBQX have been used to isolate kainate responses in hippocampal interneurons (Mulle et al., 2000) . The 2,3-benzodiazepine class of compounds such as GYKI52466 and GYKI53655 are noncompetitive antagonists showing a relatively high degree of selectivity for AMPA receptors, and these compounds have successfully been used to isolate kainate receptors (Paternain et al., 1995) . Through use of these antago-nists and cloned kainate receptors, it became clear that ATPA (Lauridsen et al., 1985) is a GLU K5 -preferring agonist potently activating homomeric GLU K5 receptors and native dorsal root ganglion kainate receptors, but shows only weak activity at AMPA receptors, and no activity at GLU K6 homomers (Clarke et al., 1997; Wilding and Huettner, 2001) .
Kainate receptors, as AMPA and NMDA receptors, are thought to be tetramers (for review, see Madden, 2002) formed by homo-or heteromeric association of the kainate receptor subunits GLU K1 , GLU K2 , GLU K5 , GLU K6 , and GLU K7 .
The first compound to be described as a competitive kainate antagonist was NS102, based on its ability to block low-affinity [ 3 H]kainate binding (Johansen et al., 1993) . However, functional assays yielded contradictory results because NS102 acts at GLU K5 and GLU K6 receptors and shows selectivity in some systems (Verdoorn et al., 1994; Wilding and Huettner, 1996) but poor selectivity in others (Paternain et al., 1996) . Recently, LY382884 has been reported to bind specifically to GLU K5 but not to GLU K6 , GLU K7 , GLU K2 , or AMPA receptor subunits (Bortolotto et al., 1999) . In functional tests, LY382884 inhibits kainate-evoked currents in dorsal root ganglion neurons and is approximately 100 times less potent on AMPA-and NMDA-evoked responses in hippocampal neurons .
Kainate receptors are believed to have diverse roles under both physiological and pathological conditions, and the novel pharmacological agents have enabled insights into the involvement of GLU K5 receptors in synaptic transmission and plasticity. In the processing of nociceptive information, kainate receptors are involved at several sites, including primary afferent fibers, superficial dorsal horn neurons, and intrinsic spinal horn neurons (Ruscheweyh and Sandkü hler, 2002) . Several studies have implicated kainate receptors (specifically, the GLU K5 subtype) in pain transmission (Procter et al., 1998; Li et al., 1999) , and Simmons et al. (1998) demonstrated that the selective GLU K5 antagonist LY382884 was active in an animal model of persistent pain. More recently, GLU K5 receptors have been linked with migraine headache, and competitive GLU K5 antagonists have been reported to be active in animal models of acute migraine (Filla et al., 2002) . Within the hippocampus, GLU K5 -containing receptors are involved in frequency facilitation and induction of long-term potentiation, and in excitatory drives of inhibitory CA1 interneurons. In addition, GLU K5 antagonists have recently been reported to have anticonvulsant activity in animal models (Smolders et al., 2002) .
Existing GLU K5 antagonists show no overt behavioral side effect at doses where the beneficial effects are observed in animal models (Simmons et al., 1998; Smolders et al., 2002) .
In summary, these data suggest that the GLU K5 subtype of kainate receptors can be used as a target for the development of selective antagonists, which may provide a valuable approach for the future treatment of pain, migraine, and epilepsy.
In the present work, we report the in vitro pharmacology of a novel noncompetitive GLU K5 antagonist. In contrast to the competitive antagonist NS1209, which inhibits AMPA-induced responses in cortical neurons (Nielsen et al., 1999) and kainate-evoked responses in cells expressing GLU K5 receptors equipotently (Varming et al., 2001 ), NS3763 did not show significant antagonistic properties on either native AMPA or native NMDA receptors. Nielsen et al., 1999; Varming et al., 2001 ) was synthesized at NeuroSearch A/S. NS3763 was identified in a compound library purchased from Chemical Diversity Labs (San Diego, CA).
Materials and Methods

Materials and Drugs
Cell culture media were obtained from Invitrogen (Roskilde, Denmark). All other chemicals were purchased from regular commercial sources and were of the purest grade available.
Cell Cultures
GLU K5 -and GLU K6 -Expressing Cell Lines. HEK293 cell lines stably expressing homomeric human GLU K5Q-1a and GLU K6IYQ were established as described previously (Varming et al., 2001) .
The cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal calf serum, in polystyrene culture flasks (175 cm 2 ), in a humidified atmosphere of 5% CO 2 , 95% air, at 37°C. Cells were cultured to 80 to 90% confluency before plating. The cells were rinsed with phosphate-buffered saline and detached from the culture flask by trypsin [0.1% (w/v)] digestion, for 5 min at 37°C. After addition of growth media, cells were resuspended by trituration and seeded at a density of 0.05 to 0.1 million cells/well in black-walled, clear-bottom 96-well plates pretreated with 0.001% (w/v) polyethyleneimine solution (75 l/well for Ն30 min). Plated cells were allowed to proliferate for 24 h before loading with dye.
For experiments with the human GLU K5Q-2b splice variant, HEK293 cells were transiently transfected using the LipofectAMINE Plus (Invitrogen) transfection kit as described by the manufacturer. Cells were used the day after transfection.
For electrophysiological studies, cells were seeded on the day of experiment. Glass coverslips (3.5 mm), precoated with poly-L-ornithine [0.005% (w/v)] and laminine [0.002% (w/v)] were placed in Petri dishes, and 2.5 ml of cell suspension (0.1 million cells/ml) was added.
Primary Cortical Neuronal Cultures. The cultures were prepared from NMRI mice (Taconic M and B, Ry, Denmark) at day 15 to 16 of gestation as described previously (Drejer et al., 1987) . Briefly, dissected tissue was chopped into 0.4-mm cubes and triturated with 0.2% (w/v) trypsin and DNase (40 g/ml), for 10 min at 37°C. The cells were suspended (1.5 million/ml) in a slightly modified DMEM (with 23 mM glucose), which contained 10% (v/v) horse serum, 7 M p-amino benzoate, 0.5 mM L-glutamine, 100 mU/l insulin, 0.1% (w/v) penicillin, and 19.1 mM KCl. The cell suspension was subsequently inoculated into poly-D-lysine-coated [0.01% (w/v)] 35-mm Petri dishes (2 ml/dish). Glass coverslips (3.5 mm) were placed in the dishes before coating. After 24 h in culture, the medium was replaced by medium without serum but with 1% N2 supplement. Every 3 to 4 days, the culture medium was replaced with DMEM/N2 supplement. Cells were maintained in culture for 8 to 13 days before experiments were carried out.
Fluorescence Measurements
On the day of experiment, the medium was aspirated from the wells, and 50 l of a 2 M Fluo-4-AM loading solution was added to each well. The plates were sealed and incubated at room temperature (20 -22°C) for 60 min. The loading medium was then aspirated, and the cells were washed twice with 100 l of buffer (10 mM HEPES, 140 mM choline chloride, 5 mM KCl, 1 mM MgCl 2 , and 10 mM CaCl 2 ; pH 7.4) to remove extracellular dye. The reason for using a relatively high CaCl 2 concentration was to enhance the fluorescent signal evoked secondary to activation of GLU K5 and GLU K6 receptors. Buffer (100 l) was added to each well, and the fluorescence was measured at room temperature (excitation 488 nm, emission 510 -570-nm band pass interference filter) using a fluorescent imaging plate reader (Molecular Devices, Sunnyvale, CA). Cells were preincubated for 1.5 min with test compound (50 l) before addition of domoate (50 l) to a final concentration of 2 M (for GLU K5 ) or 0.2 M (for GLU K6 ).
Stock solutions of test substances were made in ethanol or dimethyl sulfoxide, with final concentration of solvent never exceeding 0.5%.
Electrophysiological Studies
The electrophysiological measurements were performed in voltage clamps using conventional whole cell patch-clamp techniques (Hamill et al., 1981) , and all data were obtained with an EPC-9 amplifier (HEKA Electronics, Lambrect, Germany) run by a Macintosh G3 computer. Experimental conditions and data acquisition were set and obtained using the PULSE-software accompanying the amplifier. Data were low pass filtered and sampled directly to the hard disk. Pipettes were pulled from borosilicate glass using a horizontal electrode puller (Zeitz Instrumente, Augsburg, Germany), and the final pipette resistance was approximately 2 M⍀ when filled with internal solution and submerged in the external solution used in the experiments.
Coverslips with cultured cells were transferred to a perfusion chamber mounted on the stage of an inverted microscope supplied with Nomarski optics, and cells were continuously superfused with external solution at a rate of 2.5 ml/min.
Compounds were dissolved in external solution and applied to the patched cell through double-barreled application pipettes. The application pipettes were fabricated from theta glass tubes (1.5 mm outer diameter; WPI, Sarasota, FL). The application pipettes were mounted on a piezoelectric device (PZS-100HS; Burleigh Instruments, Quebec, Canada) connected to a piezo-driver (PZ-150M; Burleigh Instruments) driven by TTL pulses from the EPC-9 amplifier. One minute after the onset of the gravity flow, a PULSE protocol was initiated and the current was recorded three times separated by 30-s waiting periods. For transfected HEK293 cells, the duration of the recording periods was 150 ms during which the application pipette was switched to the test solution for 100 ms. For the cortical neurons, the duration of the recording period was 1.5 s, and the application pipette was moved for 1 s.
GLU K5 -or GLU K6 -Expressing Cells. For recordings from GLU K5 -or GLU K6 -expressing cells, the pipette solution contained 120 mM KCl, 31 mM KOH, 10 mM EGTA, 1.8 mM MgCl 2 , and 10 mM HEPES (pH 7.2). The external solution was composed of 140 mM NaCl, 5 mM KCl, 10 mM CaCl 2 , 1 mM MgCl 2 , and 10 mM HEPES (pH 7.4). After giga-seal formation (1-2 G⍀) and establishment of the whole cell configuration, the cells were held at a holding potential of Ϫ60 mV. For each cell, a control response induced by 3 mM Lglutamate (GLU K5 ) or 0.5 mM L-glutamate (GLU K6 ) was recorded followed by recordings of the agonist-induced responses in the presence of increasing concentrations of NS3763. Because of reversibility of the effect of NS3763 and low, constant series resistance (Ͻ5 M⍀), several concentrations could be tested on each cell. Series resistance was compensated by 80%.
Native AMPA and NMDA Receptors in Cortical Neurons. For recordings in native AMPA and NMDA receptors in cortical neurons, the pipette solution contained 135 mM CsCl, 11 mM EGTA, 1.2 mM MgCl 2 , 0.5 mM CaCl 2 , 4 mM ATP, and 10 mM HEPES (pH 7.3). The external solution was composed of 140 mM NaCl, 2 mM KCl, 2 mM CaCl 2 , 25 mM D-glucose, 0.5 M tetrodotoxin, and 10 mM HEPES (pH 7.4). After giga-seal formation (1-3 G⍀) and establishment of the whole cell configuration, the cells were held at a holding potential of Ϫ60 mV. For the measurement of AMPA responses, 4 mM MgCl 2 was added to the external solution, whereas 10 M glycine was added for the measurement of NMDA responses. Agonists (100 M AMPA or 100 M NMDA) were dissolved in the extracellular solution, and for each cell a control agonist response was recorded followed by recordings of the agonist-induced response in the presence of 30 M NS3763.
For all electrophysiological measurements, the current amplitudes were measured at the peak of the responses, and the effect of NS3763 was calculated as the amplitude during compound application divided by the amplitude of the agonist-induced current evoked before the application of compound. All experiments were performed at room temperature (20 -22°C).
Receptor Binding
GLU K5 -and GLU K6 -expressing cells were harvested and washed once with 50 mM Tris-HCl (pH 7.1) and stored at Ϫ80°C until the day of experiment. The thawed membrane pellets were resuspended in Ͼ100 volumes of ice-cold Tris-HCl buffer and centrifuged for 10 min (27,000g). The final pellets were resuspended in Tris-HCl buffer and used for binding experiments. All procedures were performed at 0 to 4°C.
Binding conditions for GLU K5 and GLU K6 were as described previously (Varming et al., 2001 
Data Analysis
In binding and functional studies, compounds were tested over a wide range of concentrations, and IC 50 values and Hill coefficients were determined based on the equation Y ϭ Bottom ϩ (Top Ϫ Bottom)/(1 ϩ (X/IC 50 ) n ), where Y is binding/calcium increase/current in percentage of total binding/calcium increase/current; X the concentration of test compound; and n is the Hill coefficient. The EC 50 values for domoate in stimulation of intracellular calcium in HEK293 cells were determined by using the equation Y ϭ 100⅐ X n /(EC 50 n ϩ X n ). Estimates of IC 50 and EC 50 values were calculated with the nonlinear curve-fitting program GraphPad Prism (version 2.0; GraphPad Software Inc., San Diego, CA). K i values were calculated from IC 50 values using the Cheng and Prusoff equation: 
Results
Calcium Measurements. Domoate concentration dependently increased intracellular calcium in GLU K5 -and GLU K6 -expressing cells with EC 50 values of 1.5 Ϯ 0.2 and 0.13 Ϯ 0.03 M, respectively (data not shown). Based on these potencies, the following inhibition studies were conducted at 2 M domoate for GLU K5 and 0.2 M for GLU K6 cells. NS3763 (Fig. 1) inhibited GLU K5 -mediated responses with an IC 50 value of 1.6 Ϯ 0.2 M, whereas no inhibition of GLU K6 -mediated response was seen at concentrations up to 30 M (n ϭ 4; Table 1; Fig. 2 ). ATPA did not induce agonist responses at concentrations ranging from 0.01 to 3 M, but the compound potently and selectively inhibited domoateinduced increase in intracellular calcium in GLU K5 cells with Table 1 ).
The competitive AMPA/kainate antagonist NS1209 potently inhibited domoate-induced calcium increase mediated by GLU K5 receptors with an IC 50 value of 0.63 Ϯ 0.09 M (n ϭ 4). GLU K6 -mediated responses were inhibited with an IC 50 value of 65 Ϯ 4 M by NS1209 (n ϭ 4; Table 1; Fig. 2) .
Electrophysiology on GLU K5 and GLU K6 Receptors. Both L-glutamate and domoate evoked concentration-dependent inward currents in cells stably expressing GLU K5 and GLU K6 receptors. The estimated EC 50 values for L-glutamate were 3.6 and 1.0 mM for GLU K5 and GLU K6 (data not shown), respectively, and for the inhibition studies 3 and 0.5 mM L-glutamate were chosen as agonist concentration for GLU K5 and GLU K6 , respectively. The peak inward current responses to 3 mM L-glutamate in GLU K5 -expressing cells ranged from 122 to 1147 pA (n ϭ 31). The L-glutamateevoked currents were considerably larger in GLU K6 -expressing cells ranging from 1.1 to 11.8 nA (n ϭ 23) at 0.5 mM L-glutamate.
In the presence of 10 M NS3763, the amplitude of the L-glutamate-evoked response in GLU K5 cells was inhibited by 44 Ϯ 10% (n ϭ 4), whereas no effect was seen on GLU K6 -mediated responses up to 30 M (n ϭ 3, Fig. 3, A and B) .
It was examined whether the effect of NS3763 was due to changes in the desensitization kinetics of GLU K5 receptors. For selected pairs of current responses evoked by 3 mM L-glutamate in the presence and absence of 30 M NS3763, the decay phase of the peak-current was fitted to a doubleexponential function and compared by paired t test. The decay time constant of the fast component, fast , in the presence of NS3763 (1.75 Ϯ 0.08 ms; n ϭ 7) was not significantly different from the control value of 1.62 Ϯ 0.10 ms (n ϭ 7). Similarly, the slow component, slow , was not different in the presence (8.87 Ϯ 1.81 ms; n ϭ 7) and absence (7.20 Ϯ 0.69 ms; n ϭ 7) of NS3763. The ratio of the two components was also unaffected by the application of the compound, the fast component accounting for 0.78 Ϯ 0.03 (control) and 0.81 Ϯ 0.04 (30 M NS3763).
Domoate was a more potent agonist than L-glutamate in evoking currents in GLU K5 -and GLU K6 -expressing cells, and the estimated EC 50 values were 7.5 and 0.4 M, respectively (data not shown). The peak inward current responses obtained at the estimated EC 50 value for domoate in GLU K5 cells ranged from 41 to 1474 pA (n ϭ 9), and the amplitude of the response evoked by 8 M domoate was inhibited by 63 Ϯ 10% in the presence of 10 M NS3763 (n ϭ 5; Fig. 4A ). NS3763 (0.01-30 M) caused a concentration-dependent inhibition of GLU K5 responses to 8 M domoate with an IC 50 value of 1.3 M, and a maximal inhibitory effect of approximately 60% (n ϭ 5; Fig. 4B ). Currents evoked by 30 M domoate were inhibited 58 Ϯ 5% (n ϭ 6) in the presence of 10 M NS3763.
All data reported above were obtained using the GLU K5-1a isoform, which contains 15 extra amino acids in the NH 2 -terminal domain and has a shorter COOH-terminal domain than the GLU K5-2b isoform reported for rat (Sommer et al., 1992) and for human by Korczak et al. (1995) . To investigate whether NS3763 had different modulatory effects at GLU K5-1a and GLU K5-2b receptors, HEK293 cells transiently expressing the GLU K5-2b isoform were used. In these cells an EC 50 value of 1.2 mM was obtained for L-glutamate (data not shown).
As illustrated in Fig. 5 , NS3763 caused a concentrationdependent inhibition of L-glutamate responses in both isoforms; however, the drug was approximately 10-fold more potent at the GLU K5-2b (IC 50 ϭ 0.38 M; n ϭ 3) than the GLU K5-1a isoform (IC 50 ϭ 5.7 M; n ϭ 4).
In electrophysiological studies, as well as in assays measuring intracellular calcium (Fig. 2) , only a partial inhibition of the responses could be obtained.
Mechanism of Action of NS3763 on GLU K5 Receptors. To investigate the mechanism of inhibition by NS3763, its effect on the concentration-response relationship for domoate was characterized. As illustrated in Fig. 6A , the maximal increase in intracellular calcium occurred at 30 M domoate, and 3 M NS3763 caused a reduction of the maximal response. However, the EC 50 value for domoate in the presence of NS3763 (1.7 Ϯ 0.2 M; n ϭ 3) was similar to the control Table 1. value of 1.4 Ϯ 0.1 M (n ϭ 3). In contrast, 3 M NS1209 caused a concentration-dependent rightward shift in the concentration-response curve with no change in the maximal response (Fig. 6A) ; the EC 50 value for domoate in the presence of 3 M NS1209 was 7.1 Ϯ 1.3 M (n ϭ 3). Thus, unlike NS1209, which interacts competitively at the domoate binding site, NS3763 inhibits domoate responses by a noncompetitive mechanism.
The noncompetitive action of NS3763 was supported by radioligand binding studies, because NS3763 did not inhibit [ 3 H]ATPA binding to GLU K5 receptors (Table 1 ). In contrast, NS1209 inhibited ligand binding to GLU K5 and GLU K6 (Varming et al., 2001) , whereas ATPA only displaced binding to GLU K5 .
The noncompetitive mechanism of action for NS3763 was confirmed in electrophysiological studies (Fig. 6B) ; the EC 50 value for L-glutamate in the presence of 10 M NS3763 (3.28 mM; n ϭ 5-9) was similar to the control value of 3.35 mM (n ϭ 3-7; p Ͼ 0.05; paired t test). Native AMPA and NMDA Receptors. The possible antagonistic activity of NS3763 on native AMPA-and NMDA receptors was investigated in cultured mouse cortical neurons. The peak inward current responses to 100 M AMPA or NMDA ranged from 104 to 244 pA (n ϭ 4) and from 525 to 1237 pA (n ϭ 4), respectively. In the presence of 30 M NS3763, the amplitude of the responses to 100 M AMPA was inhibited by Ϫ0.6 Ϯ 5.4% (n ϭ 4; Fig. 7A ). In contrast, the AMPA-induced current was blocked by 89 Ϯ 2% in the presence of 30 M GYKI52466, a noncompetitive AMPA antagonist (n ϭ 4; Fig. 7A) . The response to 100 M NMDA was blocked by 10 Ϯ 4% in the presence of 30 M NS3763 and by 79 Ϯ 11% by 50 M APV (n ϭ 4; Fig. 7B ). The inhibition of AMPA-and NMDA-induced currents by NS3763 was not significant (p Ͼ 0.05; paired t test).
Discussion
The present study shows that NS3763 selectively and noncompetitively inhibits homomeric GLU K5 receptor-mediated Fig. 3 . NS3763 selectively blocks L-glutamate-evoked currents in HEK293 cells expressing homomeric GLU K5 receptors. A, inhibition of L-glutamate-evoked current in a GLU K5 -expressing cell by 10 M NS3763. The cell was voltage clamped at Ϫ60 mV in the whole cell configuration and exposed to a 100-ms pulse of 3 mM L-glutamate. After attainment of responses of a repeatable amplitude (only one response shown), 10 M NS3763 was included in the solution as indicated by the black horizontal bar. B, effect of 30 M NS3763 on L-glutamate-evoked current in a GLU K6 -expressing cell. The experiment was performed as described above but using 0.5 mM L-glutamate. The interval between stimulations was 30 s. The recordings are representative of findings in three to four separate experiments. responses. This is the first demonstration of a noncompetitive kainate antagonist.
In studies measuring intracellular calcium, NS3763 was shown to inhibit domoate-induced responses in GLU K5 receptor-expressing HEK293 cells (IC 50 ϭ 1.6 M). ATPA and the mixed AMPA/kainate receptor antagonist NS1209 (Nielsen et al., 1999; Varming et al., 2001 ) also inhibited domoateinduced calcium responses in GLU K5 -expressing cells with IC 50 values of 0.21 and 0.63 M, respectively. The lack of agonist response observed for ATPA at concentrations up to 3 M and its inhibitory action on domoate-induced responses is most likely due to rapid desensitization of homomeric GLU K5 receptors (Lerma et al., 1993 (Lerma et al., , 2001 . Similarly, no agonist response could be obtained for L-glutamate (data not shown).
The effects of the two antagonists NS3763 and NS1209 on domoate responses, however, were different. NS1209 shifted domoate concentration-response curves to the right in a parallel manner indicative of competitive antagonism, whereas the effect of NS3763 was noncompetitive. The noncompetitive mechanism of action of NS3763 was further supported by the fact that NS3763, in contrast to ATPA and NS1209, did not inhibit [ 3 H]ATPA binding to GLU K5 receptors. In electrophysiological studies, NS3763 inhibited domoateevoked currents in GLU K5 -expressing cells (IC 50 ϭ 1.3 M), with a potency similar to that determined using intracellular calcium measurements. The inhibition of agonist-evoked currents by NS3763 was, as expected from its noncompetitive mechanism of action, independent of the concentration of agonist used. Currents evoked by 30 M domoate were inhibited by 10 M NS3763 to the same extend (58 Ϯ 5%) as seen at 8 M of the agonist (Fig. 4B) . Despite the different functional endpoints (current versus cytosolic calcium) in electrophysiological and imaging studies, the potency and maximal inhibitory effect (60 -70%) of NS3763 against domoate-induced responses were very similar.
Currents evoked by the endogenous ligand L-glutamate were also inhibited in the low micromolar range by NS3763 with a maximal inhibitory effect varying from 30 to 50% (Figs. 5 and 6B), and the noncompetitive mechanism of action of the compound was confirmed.
Furthermore, the data indicates that NS3763 is selective for homomeric GLU K5 over homomeric GLU K6 receptors at concentrations up to 30 M. NS3763 is somewhat less potent than NS1209 (IC 50 ϭ 0.075 M; Varming et al., 2001) in inhibiting GLU K5 receptor-mediated currents, but whereas NS1209 displays equipotent inhibition of AMPA-induced responses in cortical neurons (Nielsen et al., 1999) and kainate evoked responses in cells expressing GLU K5 receptors (Varming et al., 2001 ), NS3763 did not show significant antagonistic properties on either native AMPA or native NMDA receptors at concentrations up to 30 M. NS3763 thus shows selectivity for GLU K5 receptors and displays a selectivity profile different from NS1209. These data are the first describing a selective noncompetitive antagonist of GLU K5 receptors.
Several compounds interacting noncompetitively with AMPA receptors are known, and it is well described that AMPA receptor-mediated responses can be either diminished or enhanced by drugs acting at allosteric sites. The 2,3-benzodiazepines such as GYKI52466 and GYKI53655 are well characterized as negative allosteric modulators (Bleakman et al., 1996) . The known positive allosteric modulators are benzothiadiazines (e.g., cyclothiazide) and benzoylpiperidines (e.g., aniracetam and CX516). The precise mechanism by which 2,3-benzodiazepines act as negative modulators is not known; they do not affect deactivation or desensitization and are not open channel blockers (Donevan and Rogawski, 1993; Rammes et al., 1998) .
Rapid desensitization is one of the most characteristic features of kainate receptors, and modification of this feature is one of the means by which kainate receptor responses can be altered by pharmacological agents. The lectin concanavalin A has long been known to markedly reduce kainate receptor desensitization by an allosteric mechanism (Huettner, 1990) , and thereby potentiates current responses of native and recombinant receptors (Huettner, 1990; Partin et al., 1993) . The inhibition of L-glutamate-evoked currents by NS3763 is apparently not due to an increase in kainate receptor desensitization because the drug had no effect on the rate of Lglutamate current desensitization.
The binding site for NS3763 at homomeric GLU K5 receptors is not known. However, the compound seemed to distinguish between two isoforms of GLU K5 , being 10-fold more potent in inhibiting L-glutamate-evoked currents in the GLU K5-2b than in the GLU K5-1a isoform, which has 15 additional amino acids present in the NH 2 terminal (Sommer et al., 1992) . The reason for these potency differences is currently being studied.
The potencies of NS3763 in inhibiting agonist-induced responses in assays measuring intracellular calcium and in electrophysiological studies were very similar, but it seems that only a partial inhibition of the responses can be obtained. The reason for this is not known, but it should be noted that the compound has limited water solubility [Ͻ0.05 mg/ml (Ͻ125 M) at pH 7.4]. However, it cannot be excluded that NS3763 is unable to inhibit the functional responses completely due to its noncompetitive interaction with the GLU K5 receptor.
ATPA has been shown to be not completely selective for homomeric GLU K5 receptors because it also activates heteromeric GLU K5 receptors containing GLU K2 or GLU K6 subunits and heteromers consisting of GLU K6/K2 receptor subunits (Paternain et al., 2000) . LY382884 has recently been reported to also be effective against heteromeric assemblies of GLU K5 and GLU K6 subunits (Smolders et al., 2002) , so there is still a need for new pharmacological tools. The activity of NS3763 on heteromeric kainate receptors and the potential analgesic effect of the drug in animal models of pain are currently being studied.
